title: Responsive theranostic systems: integration of diagnostic imaging agents and responsive controlled release drug delivery carriers.
abstract: For decades, researchers and medical professionals have aspired to develop mechanisms for noninvasive treatment and monitoring of pathological conditions within the human body. The emergence of nanotechnology has spawned new opportunities for novel drug delivery vehicles capable of concomitant detection, monitoring, and localized treatment of specific disease sites. In turn, researchers have endeavored to develop an imaging moiety that could be functionalized to seek out specific diseased conditions and could be monitored with conventional clinical imaging modalities. Such nanoscale detection systems have the potential to increase early detection of pathophysiological conditions because they can detect abnormal cells before they even develop into diseased tissue or tumors. Ideally, once the diseased cells are detected, clinicians would like to treat those cells simultaneously. This idea led to the concept of multifunctional carriers that could target, detect, and treat diseased cells. The term "theranostics" has been created to describe this promising area of research that focuses on the combination of diagnostic detection agents with therapeutic drug delivery carriers.  Targeted theranostic nanocarriers offer an attractive improvement to disease treatment because of their ability to execute simultaneous functions at targeted diseased sites. Research efforts in the field of theranostics encompass a broad variety of drug delivery vehicles, imaging contrast agents, and targeting modalities for the development of an all-in-one, localized detection and treatment system. Nanotheranostic systems that utilize metallic or magnetic imaging nanoparticles can also be used as thermal therapeutic systems. This Account explores recent advances in the field of nanotheranostics and the various fundamental components of an effective theranostic carrier.
authors.affiliation: Department of Chemical Engineering, The University of Texas at Austin, Austin, Texas 78712, USA.
authors.forename: Mary E
authors.initials: ME
authors.lastname: Caldorera-Moore
authors.forename: William B
authors.initials: WB
authors.lastname: Liechty
authors.forename: Nicholas A
authors.initials: NA
authors.lastname: Peppas
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D003692:Delayed-Action Preparations; D003952:Diagnostic Imaging / Q000379:methods*; D004337:Drug Carriers / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D058990:Molecular Targeted Therapy; D050997:Nanomedicine / Q000379:methods*; D053758:Nanoparticles / Q000737:chemistry / Q000627:therapeutic use
chemical_list: D003692:Delayed-Action Preparations; D004337:Drug Carriers